<DOC>
	<DOC>NCT02009449</DOC>
	<brief_summary>This is a first-in-human, open-label, dose escalation study to evaluate the safety and tolerability of AM0010 in patients with advanced solid tumors, dosed daily subcutaneously as a monotherapy or in combination with chemotherapy or immunotherapy.</brief_summary>
	<brief_title>A Phase 1 Study of AM0010 in Patients With Advanced Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma, Renal Cell</mesh_term>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Pembrolizumab</mesh_term>
	<mesh_term>Nivolumab</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<criteria>Part A Escalation Cohorts: o Histologically or cytologically confirmed advanced malignant solid tumor, limited to melanoma, castrate resistant prostate cancer (CRPC), ovarian cancer (OVCA), renal cell carcinoma, colorectal carcinoma (CRC), pancreatic carcinoma or nonsmall cell lung carcinoma (NSCLC) that is refractory to, intolerant of, for which no standard of therapy is available or where the patient refuses existing therapies Part A Expansion Cohorts, Part B and C Escalation and Expansion Cohorts: Tumors with all histological diagnosis or tissue origin may be enrolled Patients must have failed prior standard curative chemotherapy for their disease, refuse existing therapies OR the proposed chemotherapy regimen to which AM0010 is added represents an acceptable standard treatment for their disease. Measurable or evaluable disease according to irRC or bone metastatic disease evaluable by Prostate Cancer Working Group 2 criteria (PCWG2) for castrationresistant prostate cancer (CRPC) At least 18 years of age Performance Status of 0 or 1 Adequate organ function Hematologic malignancies Pregnant or lactating Present or history of neurological disorders such as Multiple Sclerosis and Guillain Barre or inflammatory central nervous system/peripheral nervous system (CNS/PNS) disorders Myocardial infarction within the last 6 months Unstable angina, or unstable cardiac arrhythmia requiring medication Surgery within the last 28 days Systemic fungal, bacterial, viral, or other infection History of bleeding diathesis within the last 6 months Positive for human immunodeficiency virus (HIV), hepatitis C, or hepatitis B</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Phase 1/Phase 1b</keyword>
	<keyword>Oncology</keyword>
	<keyword>Cancer</keyword>
	<keyword>Solid Tumors</keyword>
</DOC>